Efficacy of late postnatal dexamethasone on weaning from invasive mechanical ventilation in extreme premature infants.
Journal
Journal of perinatology : official journal of the California Perinatal Association
ISSN: 1476-5543
Titre abrégé: J Perinatol
Pays: United States
ID NLM: 8501884
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
01
06
2020
accepted:
18
05
2021
revised:
16
03
2021
pubmed:
30
5
2021
medline:
21
10
2021
entrez:
29
5
2021
Statut:
ppublish
Résumé
To evaluate the short-term respiratory effects of PND in a cohort of ventilator-dependent premature infants. Clinical data from 106 infants 23-28 weeks gestation who received PND for weaning from MV during 2011-2017 were evaluated. PND was started at a dose of 0.1 mg/kg/d tapered over 5-7 d. Treatment success was defined as extubated and free from MV on d14 after start of treatment. Treatment was successful in 83 (78%) infants. Demographics and age of treatment did not differ between groups. In the failure group, a higher proportion were on HFOV and FiO In most infants, PND resulted in successful weaning from MV. Reduced need for oxygen in infants not extubated may be beneficial, but it is unknown if this offsets the risks. The long-term effects PND in ventilator dependent infants need to be evaluated.
Identifiants
pubmed: 34050243
doi: 10.1038/s41372-021-01108-4
pii: 10.1038/s41372-021-01108-4
pmc: PMC8161346
doi:
Substances chimiques
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1951-1955Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr. 1979;95:819–23. (5 Pt 2)
doi: 10.1016/S0022-3476(79)80442-4
Northway WH Jr., Moss RB, Carlisle KB, Parker BR, Popp RL, Pitlick PT, et al. Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med. 1990;323:1793–9.
doi: 10.1056/NEJM199012273232603
Taghizadeh A, Reynolds EO. Pathogenesis of bronchopulmonary dysplasia following hyaline membrane disease. Am J Pathol. 1976;82:241–64.
pubmed: 175660
pmcid: 2032400
Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Late (>7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017;10:CD001145.
pubmed: 29063594
Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics. 1985;75:106–11.
pubmed: 3880879
Bergenfeldt M, Axelsson L, Ohlsson K. Release of neutrophil proteinase 4(3) and leukocyte elastase during phagocytosis and their interaction with proteinase inhibitors. Scand J Clin Lab Invest. 1992;52:823–9.
doi: 10.3109/00365519209088387
Couser JI Jr., Berley J, Timm EG. Intrapleural urokinase for loculated effusion. Chest. 1992;101:1467–9.
doi: 10.1378/chest.101.5.1467
Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (<8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017;10:CD001146.
pubmed: 29063585
Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004;350:1304–13.
doi: 10.1056/NEJMoa032089
Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB, Investigators DS. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics. 2007;119:716–21.
doi: 10.1542/peds.2006-2806
Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB, Investigators DS. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006;117:75–83.
doi: 10.1542/peds.2004-2843
Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics. 2005;115:655–61.
doi: 10.1542/peds.2004-1238
Zeng L, Tian J, Song F, Li W, Jiang L, Gui G, et al. Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: a network meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2018;103:F506–F11.
doi: 10.1136/archdischild-2017-313759
Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr. 2014;165:1258–60.
doi: 10.1016/j.jpeds.2014.07.049
Yates HL, Newell SJ. Minidex: very low dose dexamethasone (0.05 mg/kg/day) in chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2011;96:F190–4.
doi: 10.1136/adc.2010.187203
Kuschel C, Evans N, Lam A. Prediction of individual response to postnatal dexamethasone in ventilator dependent preterm infants. Arch Dis Child Fetal Neonatal Ed. 1998;78:F199–203.
doi: 10.1136/fn.78.3.F199
Nath S, Reynolds AM, Lakshminrusimha S, Ma C, Hudak ML, Ryan RM. Retrospective analysis of short-term respiratory outcomes of three different steroids used in clinical practice in intubated preterm infants. Am J Perinatol. 2019. Epub 2019/08/06. https://doi.org/10.1055/s-0039-1694004 . PubMed PMID: 31382299.
Tanney K, Davis J, Halliday HL, Sweet DG. Extremely low-dose dexamethasone to facilitate extubation in mechanically ventilated preterm babies. Neonatology. 2011;100:285–9.
doi: 10.1159/000326273
Cuna A, Govindarajan S, Oschman A, Dai H, Brophy K, Norberg M, et al. A comparison of 7-day versus 10-day course of low-dose dexamethasone for chronically ventilated preterm infants. J Perinatol. 2017;37:301–5.
doi: 10.1038/jp.2016.215
Costeloe KL, Hennessy EM, Haider S, Stacey F, Marlow N, Draper ES. Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies). BMJ. 2012;345:e7976.
doi: 10.1136/bmj.e7976
Onland W, Offringa M, De Jaegere AP, van Kaam AH. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics. 2009;123:367–77.
doi: 10.1542/peds.2008-0016
Harmon HM, Jensen EA, Tan S, Chaudhary AS, Slaughter JL, Bell EF, et al. Timing of postnatal steroids for bronchopulmonary dysplasia: association with pulmonary and neurodevelopmental outcomes. J Perinatol. 2020;40:616–27.
doi: 10.1038/s41372-020-0594-4